NEW ATAI-Logo_Primary.png
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
February 06, 2024 17:00 ET | atai Life Sciences
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
January 04, 2024 07:00 ET | atai Life Sciences
Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
January 02, 2024 08:00 ET | atai Life Sciences
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD)...
NEW ATAI-Logo_Primary.png
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
November 14, 2023 07:03 ET | atai Life Sciences
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
October 06, 2023 16:05 ET | atai Life Sciences
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
October 02, 2023 16:13 ET | atai Life Sciences
VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profilePharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 14, 2023 08:02 ET | atai Life Sciences
NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in Upcoming September Investor Conferences
September 06, 2023 16:01 ET | atai Life Sciences
NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW ATAI-Logo_Primary.png
atai Life Sciences gibt Finanzergebnisse des zweiten Quartals 2023 und operative Highlights sowie klinische Daten aus der Phase-1-Studie mit DMX-1002 (Ibogain) bekannt
August 14, 2023 05:10 ET | atai Life Sciences
Mehrere Wirkstoffe im fortgeschrittenen klinischen Stadium der Entwicklung, einschließlich der laufenden Phase-2b-Studie zu RL-007 für Patienten mit kognitiver Beeinträchtigung im Zusammenhang mit...
NEW ATAI-Logo_Primary.png
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
August 10, 2023 06:59 ET | atai Life Sciences
Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with SchizophreniaDMX-1002 (Ibogaine) Phase 1...